Harrow Health, Inc.
NASDAQ:HROWDrug Manufacturers - Specialty & Generic
+$0.12 today
- Market cap
- $1.21B
- Beta
- 0.28
- P/E (TTM)
- -104.7
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.75M
HROW Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Harrow Health, Inc.NASDAQ: HROW
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 49.5% from a year ago
Total equity stood at $28.35M at the end of Q1 FY2026, down 49.5% from a year earlier and down 45.6% from the prior quarter. Over 3 fiscal years it compounded at +24.1% a year.
Context
- Total equity amounted to 6.8% of total assets at the end of Q1 FY2026, down 8.6 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -49.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 52.09M USD
- Year-over-year change
- -24.8%
- 4-year CAGR
- +47.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 52.09M | -24.8% |
| FY2024 | 2024-12-31 | 69.3M | -1.0% |
| FY2023 | 2023-12-31 | 70M | +157.0% |
| FY2022 | 2022-12-31 | 27.24M | +149.2% |
| FY2021 | 2021-12-31 | 10.93M | — |
Total Equity vs competitors
How HROW compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -49.5% is the 7th highest of 8, against a peer median of -1.0%.
- Total equity amounts to 6.8% of total assets for HROW, versus a peer median of 62.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $6.44B USD | -1.0% | -2.8% | 46.5% | |
| Mar 2026 | $581.57M USD | +118.7% | +164.5% | 79.4% | |
| Mar 2026 | $230.47M USD | -22.8% | +47.0% | 80.0% | |
| Mar 2026 | CHF 196.06M CHF | +20.6% | — | 80.6% | |
| Sep 2026 | $104.03M USD | -69.0% | +21.2% | 20.6% | |
| Mar 2026 | $28.35M USD | -49.5% | +24.1% | 6.8% | |
| Sep 2026 | $12.57M USD | -46.9% | -28.8% | 6.0% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $6.12M USD | — | — | 32.8% |
| Mar 2026 | -$28.99M USD | +10.7% | — | 132.4% | |
| Peer median (excluding HROW) | — | -1.0% | +21.2% | 62.9% | |
Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 42.17M | 96.27M | 74.09M | 47.25M | 72.93M |
| Short-term Investments | 8.5M | 5.59M | 8.68M | 0 | 0 |
| Net Receivables | 4.52M | 6.39M | 36.49M | 116.6M | 110.9M |
| Inventory | 4.22M | 6.54M | 10.87M | 10.7M | 13.52M |
| Other Current Assets | 92K | 118K | 1.75M | 3.41M | 2.13M |
| Total Current Assets | 60.66M | 118.26M | 139.07M | 189.65M | 211.75M |
| Property, Plant & Equipment (Net) | 9.08M | 11M | 12.44M | 12.29M | 11.04M |
| Goodwill | 332K | 332K | 332K | 332K | 332K |
| Intangible Assets | 17.13M | 25.84M | 159.91M | 186.7M | 175.17M |
| Long-term Investments | 11.13M | 0 | 0 | 0 | 0 |
| Tax Assets | (12.45M) | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 12.45M | 1.95M | 0 | 0 | 1.18M |
| Total Non-current Assets | 37.67M | 39.12M | 172.68M | 199.32M | 187.73M |
| Total Assets | 98.33M | 157.38M | 311.76M | 388.97M | 399.48M |
| Account Payables | 5.17M | 6.44M | 21.42M | 38.76M | 35.36M |
| Short-term Debt | 0 | 0 | 806K | 0 | 887K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 16K | 113K | 0 | 44K | 788K |
| Other Current Liabilities | 1.16M | 0 | 21.66M | 0 | 59.27M |
| Total Current Liabilities | 9.72M | 18.63M | 49.34M | 91.34M | 96.3M |
| Long-term Debt | 71.65M | 104.17M | 183.17M | 219.54M | 243.18M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 2.71M | 0 | 0 |
| Total Non-current Liabilities | 77.68M | 111.51M | 192.41M | 228.33M | 251.09M |
| Total Liabilities | 87.4M | 130.14M | 241.75M | 319.67M | 347.39M |
| Common Stock | 27K | 30K | 35K | 35K | 37K |
| Retained Earnings | (95.41M) | (109.49M) | (133.9M) | (151.39M) | (156.52M) |
| Accumulated OCI | 0 | 0 | (409K) | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | (355K) | (355K) | (355K) | (355K) | (355K) |
| Total Equity | 10.93M | 27.24M | 70M | 69.3M | 52.09M |
| Total Debt | 77.96M | 112.23M | 190.5M | 228.83M | 251.98M |
| Net Debt | 35.79M | 15.96M | 116.42M | 181.58M | 179.05M |
Harrow Health, Inc.
NASDAQ:HROW
Intrinsic Alpha fair value
Locked
Current Price
$32.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.